Aclaris Therapeutics/$ACRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Ticker
$ACRS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
63
ISIN
US00461U1051
Website
ACRS Metrics
BasicAdvanced
$169M
-
-$1.45
0.43
-
Price and volume
Market cap
$169M
Beta
0.43
52-week high
$4.07
52-week low
$0.99
Average daily volume
698K
Financial strength
Current ratio
5.057
Quick ratio
4.907
Long term debt to equity
1.379
Total debt to equity
1.724
Management effectiveness
Return on assets (TTM)
-18.20%
Return on equity (TTM)
-91.03%
Valuation
Price to revenue (TTM)
7.909
Price to book
1.17
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-2.87
Growth
Revenue change (TTM)
-42.87%
Earnings per share change (TTM)
32.32%
3-year revenue growth (CAGR)
40.30%
3-year earnings per share growth (CAGR)
2.08%
What the Analysts think about ACRS
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
ACRS Financial Performance
Revenues and expenses
ACRS Earnings Performance
Company profitability
ACRS News
AllArticlesVideos
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
GlobeNewsWire·1 week ago
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewsWire·4 weeks ago
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aclaris Therapeutics stock?
Aclaris Therapeutics (ACRS) has a market cap of $169M as of June 06, 2025.
What is the P/E ratio for Aclaris Therapeutics stock?
The price to earnings (P/E) ratio for Aclaris Therapeutics (ACRS) stock is 0 as of June 06, 2025.
Does Aclaris Therapeutics stock pay dividends?
No, Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Aclaris Therapeutics dividend payment date?
Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aclaris Therapeutics?
Aclaris Therapeutics (ACRS) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.